GlassScriptPhysician profile
Achini P Dingman
NPI 1174594758
$2,022.09
in general payments reported to CMS, 2019-2025
17 companies · $386 in 2025
The $386 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $79.11 · 2023: $760 · 2024: $431 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.10 |
| Education | $205.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $797.84 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $318.96 | 2019-2024 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $253.53 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Sobi, INC | $149.03 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $128.92 | 2019 | |
| Pfizer INC. | $91.65 | 2019-2023 | |
| Abbvie INC. | $60.78 | 2019-2023 | Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $55.46 | 2019-2024 | Orencia |
| Genentech USA, INC. | $39.11 | 2023-2024 | Actemra, Rituxan |
| Celgene Corporation | $33.23 | 2019-2024 | Orencia |
| Organon LLC | $24.60 | 2024-2025 | Hadlima |
| Glaxosmithkline, LLC. | $18.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.28 | 2023 | Saphnelo |
| Horizon Therapeutics Plc | $13.04 | 2023 | Krystexxa |
| Lilly USA, LLC | $12.27 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $11.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Achini Dingman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.